David E Cohn MD

David E Cohn MD
ProfessorCollege of Medicinecohn.30@osu.edu
M210 Starling Loving Hall 320 W 10th Avenue Columbus Ohio 43210
Phone:614-293-7642Fax: 614-293-3078
  • Experimental Therapeutics

General Research Interest

I am interested in gynecologic cancers, from both a clinical, translational and basic science perspective.  The division of gynecologic oncology has many rich research collaborations with other members of the CCC. 

Research Description

My research focus includes identification of novel biomarkers in ovarian cacner for early detection and prevention.  We have investigated the role of micrRNA from blood as a biomarker for ovarian cancer, and have developed a vaccine targeting pro-angiogenic molecules in this disease.  Furtheromre, we are investigating the role of the TGF beta pathway in cervical cancer susceptibility as well as the ability of lyopholized black raspberries to prevent cervical cancer.

Transinstitutional Work

We are collaborating with the Fred Hutchinson in the investigation of microRNAs as ovarian cancer biomarkers, and with Washington University and the University of West Virginia in the identification of TGF beta pathways that underlie cervical cancer.

Current Publications

  • Selvendiran KHO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer.Cancer Res 74 2316-27 4/15/2014
  • Suarez AAMismatch repair protein expression in 1049 endometrial carcinomas, associations with body mass index, and other clinicopathologic variables.Gynecol Oncol 133 43-7 4/1/2014
  • Eisenhauer ELFeasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer-A Phase 1 Study.Int J Gynecol Cancer 3/19/2014
  • White EAssociations of long-chain ?-3 fatty acids and fish intake with endometrial cancer risk in the VITamins And Lifestyle cohort.Am J Clin Nutr 99 599-608 3/1/2014
  • Monk BJPhase III randomized trial of weekly cisplatin and irradiation versus cisplatin and tirapazamine and irradiation in stages IB2, IIA, IIB, IIIB, and IVA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study.J Clin Oncol 32 458-64 2/10/2014
  • Zighelboim I, Mutch DG, Knapp A, Ding L, Xie M, Cohn DE, Goodfellow PJHigh frequency strand slippage mutations in CTCF in MSI-positive endometrial cancers.Hum Mutat 35 63-5 1/1/2014
  • Barnett JC, Alvarez Secord A, Cohn DE, Leath CA 3rd, Myers ER, Havrilesky LJCost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.Cancer 119 3653-61 10/15/2013
  • Liang MI, Rosen MA, Rath KS, Clements AE, Backes FJ, Eisenhauer EL, Salani R, O'Malley DM, Fowler JM, Cohn DEReducing readmissions after robotic surgical management of endometrial cancer:A potential for improved quality care.Gynecol Oncol in press 10/4/2013
  • Cohn DE, Leitao M, Levenback C, Berkowitz R, Roman L, Lucci J, Kim S, Lancaster J, Odunsi K, Wakabayashi M, Goff BAReporting of quality measures in gynecologic oncology programs at Prospective Payment System (PPS)-Exempt Cancer Hospitals: an early glimpse into a challenging initiative.Gynecol Oncol 130(3) 403-6 9/1/2013
  • Smith B, Cohn DE, Clements A, Tierney BJ, Straughn JM JrIs the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis.Gynecol Oncol 130(3) 416-20 9/1/2013
  • Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, Valea FA, Secord AA, Lippmann LT, Dehdashti F, Rader JSMulticenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer.Gynecol Oncol 130(1) 64-8 7/1/2013
  • Backes FJ, Richardson DL, McCann GA, Smith B, Salani R, Eisenhauer EL, Fowler JM, Copeland LJ, Cohn DE, O'Malley DMShould bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?Int J Gynecol Cancer 23(5) 833-8 6/1/2013
  • Rath KS, McCann GA, Cohn DE, Rivera BK, Kuppusamy P, Selvendiran KSafe and targeted anticancer therapy for ovarian cancer using a novel class of curcumin analogs.J Ovarian Res 6(1) 35 5/11/2013
  • Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, Cohn DE, Walker JL, Moore RG, Downs LS, Soslow RA, Zaino REtiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.Gynecol Oncol 129(2) 277-84 5/1/2013
  • McCann GA, Boutsicaris CE, Preston MM, Backes FJ, Eisenhauer EL, Fowler JM, Cohn DE, Copeland LJ, Salani R, O'Malley DMNeuroendocrine carcinoma of the uterine cervix: the role of multimodality therapy in early-stage disease.Gynecol Oncol 129(1) 135-9 4/1/2013
  • Rath KS, Loseth D, Muscarella P, Phillips GS, Fowler JM, O'Malley DM, Cohn DE, Copeland LJ, Eisenhauer EL, Salani ROutcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian cancer.Gynecol Oncol 129(1) 103-6 4/1/2013
  • Villalona-Calero MAAssessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.Transl Res 161(3) 156-64 3/1/2013
  • Clements AE, Tierney BJ, Cohn DE, Straughn JM JrIs selective lymphadenectomy more cost-effective than routine lymphadenectomy in patients with endometrial cancer?Gynecol Oncol 128(2) 166-70 2/1/2013
  • Hess LM, Brady WE, Havrilesky LJ, Cohn DE, Monk BJ, Wenzel L, Cella DComparison of methods to estimate health state utilities for ovarian cancer using quality of life data: a Gynecologic Oncology Group study.Gynecol Oncol 128(2) 175-80 2/1/2013
  • Brudie LA, Backes FJ, Ahmad S, Zhu X, Finkler NJ, Bigsby GE 4th, Cohn DE, O'Malley D, Fowler JM, Holloway RWAnalysis of disease recurrence and survival for women with uterine malignancies undergoing robotic surgery.Gynecol Oncol 128(2) 309-15 2/1/2013
  • Backes FJ, Tierney BJ, Eisenhauer EL, Bahnson RR, Cohn DE, Fowler JMComplications after double-barreled wet colostomy compared to separate urinary and fecal diversion during pelvic exenteration: time to change back?Gynecol Oncol 128(1) 60-4 1/1/2013
  • Brasky TM, Moysich KB, Cohn DE, White ENon-steroidal anti-inflammatory drugs and endometrial cancer risk in the VITamins And Lifestyle (VITAL) cohort.Gynecol Oncol 128(1) 113-9 1/1/2013
  • McCann GA, Taege SK, Boutsicaris CE, Phillips GS, Eisenhauer EL, Fowler JM, O'Malley DM, Copeland LJ, Cohn DE, Salani RThe impact of close surgical margins after radical hysterectomy for early-stage cervical cancer.Gynecol Oncol 128(1) 44-8 1/1/2013
  • Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, Lee A, Bacot F, Vincent D, Hogervorst FB, Peock S, Stoppa-Lyonnet D, Jakubowska A, Investigators K, Radice P, Schmutzler RK, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M, Hansen TV, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Ewart Toland A, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey MC, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo SH, Ganz PA, Campbell I, van der Hout AH, van Deurzen CH, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HE, Gille JJ, Ausems MG, Blok MJ, Ligtenberg MJ, Rookus MA, Devilee P, Verhoef S, van Os TA, Wijnen JT, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Izatt L, Eeles RA, Adlard J, Eccles DM, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, Bignon YJ, Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschmidt B, Weber BH, Arver B, Stenmark-Askmalm M, Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Lindor NM, Kaufman B, Shimon Paluch S, Laitman Y, Skytte AB, Gerdes AM, Pedersen IS, Moeller ST, Kruse TA, Jensen UB, Vijai J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozcelik H, Ejlertsen B, Nielsen FC, Jønson L, Andersen MK, Ding YC, Steele L, Foretova L, Teulé A, Lazaro C, Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero A, de la Hoya M, Aittomäki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, Miron A, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, Tihomirova L, Friebel TM, Agnarsson BA, Lu KH, Lejbkowicz F, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, Pastinen T, Pankratz VS, Offit K, Easton DF, Chenevix-Trench G, Antoniou ACGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.PLoS Genet 9(3) e1003212 1/1/2013
  • McCann GA, Smith B, Backes FJ, Rath K, Chacko S, Salani R, Eisenhauer E, Fowler J, Cohn D, O'Malley DRecurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?Gynecol Oncol 127(2) 362-6 11/1/2012
  • Nuovo GJ, Garofalo M, Valeri N, Roulstone V, Volinia S, Cohn DE, Phelps M, Harrington KJ, Vile R, Melcher A, Galanis E, Sehl S, Adair R, Scott K, Rose A, Toogood G, Coffey MCReovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples.Mod Pathol 25(10) 1333-44 10/1/2012
  • Cantrell LA, Havrilesky L, Moore DT, O'Malley D, Liotta M, Secord AA, Nagel CI, Cohn DE, Fader AN, Wallace AH, Rose P, Gehrig PAA multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.Gynecol Oncol 127(1) 22-6 10/1/2012
  • Fader AN, Seamon LG, Escobar PF, Frasure HE, Havrilesky LA, Zanotti KM, Secord AA, Boggess JF, Cohn DE, Fowler JM, Skafianos G, Rossi E, Gehrig PAMinimally invasive surgery versus laparotomy in women with high grade endometrial cancer: a multi-site study performed at high volume cancer centers.Gynecol Oncol 126(2) 180-5 8/1/2012
  • Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Shimon-Paluch S, Kaufman B, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Gronwald J, Huzarski T, Cybulski C, Byrski T, Osorio A, Ramony Cajal T, Stavropoulou AV, Benítez J, Hamann U, Rookus MA, Aalfs CM, de Lange J, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Gomez-Garcia EB, Hoogerbrugge N, Jager A, van der Luijt RB, Easton DF, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Izatt L, Eeles RA, Adlard J, Davidson R, Eccles DM, Cole T, Cook J, Brewer C, Tischkowitz M, Godwin AK, Pathak HB, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Barjhoux L, Leone M, Gauthier-Villars M, Caux-Moncoutier V, de Pauw A, Hardouin A, Berthet P, Dreyfus H, Fert Ferrer S, Collonge-Rame MA, Sokolowska J, Buys SS, Daly MB, Miron A, Terry MB, Chung WK, John EM, Southey MC, Goldgar DE, Singer CF, Tea Maria MK, Gschwantler-Kaulich D, Fink-Retter A, Hansen TV, Ejlertsen B, Johannsson OT, Offit K, Sarrel K, Gaudet MM, Vijai J, Robson ME, Piedmonte M, Andrews L, Cohn DE, Demars LR, Disilvestro P, Rodriguez GC, Toland AE, Montagna M, Agata S, Imyanitov EN, Isaacs C, Janavicius R, Lazaro C, Blanco I, Ramus SJ, Sucheston LE, Karlan BY, Gross J, Ganz PA, Beattie MS, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Nevanlinna H, Aittomäki K, Simard J, Spurdle AB, Beesley J, Chen X, Tomlinson GE, Weitzel JN, Garber JE, Olopade FI, Rubinstein WS, Tung N, Blum JL, Narod SA, Brummel S, Gillen DL, Lindor NM, Fredericksen Z, Pankratz VS, Couch FJ, Radice P, Peterlongo P, Greene MH, Loud JT, Mai PL, Andrulis IL, Glendon G, Ozcelik H, Gerdes AM, Thomassen M, Jensen UB, Skytte AB, Caligo MA, Lee A, Chenevix-Trench G, Antoniou AC, Neuhausen SLA nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Cancer Epidemiol Biomarkers Prev 21(8) 1362-70 8/1/2012
  • Mercado RC, Hampel H, Kastrinos F, Steyerberg E, Balmana J, Stoffel E, Cohn DE, Backes FJ, Hopper JL, Jenkins MA, Lindor NM, Casey G, Haile R, Madhavan S, de la Chapelle A, Syngal SPerformance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases.Genet Med 14(7) 670-80 7/1/2012
  • Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran KHO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.Cancer Biol Ther 13(9) 766-75 7/1/2012
  • Backes FJ, Brudie LA, Farrell MR, Ahmad S, Finkler NJ, Bigsby GE, O'Malley D, Cohn DE, Holloway RW, Fowler JMShort- and long-term morbidity and outcomes after robotic surgery for comprehensive endometrial cancer staging.Gynecol Oncol 125(3) 546-51 6/1/2012
  • Havrilesky LJ, Garfield CF, Barnett JC, Cohn DEEconomic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer.Gynecol Oncol 125(3) 631-4 6/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu